Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001 -    First dose level rated as safe by independent Data Safety Monitoring Board-    Second dose level to be administered according to plan-    THE001 designed as targeted tumor treatment independent...

Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001 -    Addressing high unmet medical need in locally advanced soft tissue sarcoma-    Targeted tumor treatment independent of specific molecular targets or tumor subtypes Munich, Germany – May 24,...